New Agents in Multiple Myeloma: An Examination of Safety Profiles

Sara Bringhen; Edwin de Wit; Meletios A Dimopoulos

doi:10.1016/j.clml.2017.05.003

Related publications

Article2009

Multiple Myeloma in the Era of Novel Agents

Meletios A Dimopoulos, Michel Attal

Article2025

Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma

Anastasios Tentolouris, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Ernesto Ruiz Duque, Meletios A Dimopoulos, Αlexandros Briasoulis, Maria Gavriatopoulou

Article2010

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios A Dimopoulos, Michèle Cavo, Gareth J. Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet‐Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans Erik Johnsen, Joan Bladé, Jesús F. San Miguel, Antonio Palumbo

Article2007

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

Evangelos Terpos, Meletios A Dimopoulos, Orhan Sezer

Article2011

Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

Heinz Ludwig, Meral Beksaç, Joan Bladé, Jamie Cavenagh, Michèle Cavo, Michel Delforge, Meletios A Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Façon, Hartmut Goldschmidt, Jean‐Luc Harousseau, U Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen‐Nativ, Л. П. Менделеева, Hareth Nahi, Torben Plesner, Jesús F. San Miguel, Pieter Sonneveld, Miklós Udvardy, Pia Sondergeld,

New Agents in Multiple Myeloma: An Examination of Safety Profiles

Discussion(0)